BridgeMD
Compares treatment options for Androgenetic Alopecia (AGA)
Official title VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
ClinicalTrials.gov ID: NCT07536100
What this study is testing
What is Topical minoxidil?
Topical minoxidil is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for androgenetic alopecia (aga).
Also referred to as Topical Minoxidil 2% solution.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female participants aged ≥18 years.
- Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
- Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
- Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
- Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.
You likely can't join if
- Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal...
- History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
- Psychiatric disorders or other conditions that may affect participant safety or compliance.
- Pregnant or breastfeeding women. Hair and scalp-related exclusions:
- Diffuse hair thinning involving the occipital area.
- Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).
See the full eligibility criteria
- Male or female participants aged ≥18 years.
- Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
- Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
- Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
- Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.
- Able to attend all scheduled visits during the 24-week study period.
- Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).
- History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
- Psychiatric disorders or other conditions that may affect participant safety or compliance.
- Pregnant or breastfeeding women. Hair and scalp-related exclusions:
- Diffuse hair thinning involving the occipital area.
- Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).
- History of hair transplantation at any time or hair extensions within 6 months prior to screening.
- Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.
- Use of light/laser therapy on the scalp within 3 months prior to screening.
- Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.
- Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.
- Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening. Medication-related exclusions:
- Known hypersensitivity to study-related products or ingredients.
- Use of dutasteride within 12 months prior to screening.
- Use of systemic cytotoxic agents.
- Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp).
- Use within 6 months prior to screening of:
- Minoxidil (topical or oral)
- Finasteride (topical or oral)
- Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide)
- Prostaglandin analogs applied to the scalp
- Estrogen or progesterone topical preparations
- Tamoxifen
- Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)
- Drugs associated with hair loss (e.g., valproic acid)
- Participation in another clinical trial within 1 month prior to screening or during this study.
The study team makes the final eligibility decision.
Where it's taking place
- Bangkok, Bangkok, Thailand
- Bangkok, Thailand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bangkok, Bangkok, Thailand; Bangkok, Thailand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.